In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AHP's Wyeth-Ayerst in co-promotion with King

Executive Summary

AHP's Wyeth-Ayerst Laboratories unit licensed co-promotion rights in the US and Puerto Rico to King Pharmaceuticals' (acquires or develops branded pharmaceuticals and sells them) cardiovascular and hypertension drug Altace (ramipril) for an eight-year term (automatically extendible if King gets additional patents or exclusivity on the drug). In return, AHP is turning over US and Puerto Rican rights to its oral contraceptive Nordette (levonorgestrel, ethinyl oestradiol) and two other undisclosed products for $200mm (of which AHP loaned King $25mm).

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)
    • Product or Technology Swap
    • Product Purchase

Related Companies